Number of pending claims pertaining to a loss contingency.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

Contingencies (Details)	May 03, 2022 USD ($)	Sep. 18, 2020 cause	Dec. 05, 2019 cause	Sep. 22, 2016 state
Loss Contingencies [Line Items]
Number of states that brought a lawsuit \| state				41
Humana Inc. v. Aquestive Therapeutics, Inc.
Loss Contingencies [Line Items]
Pending claim		5
Neurelis, Inc. v. Aquestive Therapeutics, Inc.
Loss Contingencies [Line Items]
Pending claim			3
Litigation settlement, amount awarded from other party \| $	$ 155,907.5